Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Real World Data Helping To Drive Rise Of Novartis' Entresto

Executive Summary

Patients with heart failure on Entresto say they have fewer symptoms and greater quality of life, according to a registry study and Novartis is hoping that this and other real world data will propel the drug towards its peak sales target of $5bn.

Advertisement

Related Content

Pivotal Trials Are Cheaper For Unmet Needs And Orphan Drugs, JAMA Study Finds
Novartis Pharma CEO On Star Products, Pricing And Rebates
Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern
Pharma Q2 Results Preview: Johnson & Johnson And Novartis
Novartis' Late Bloomer Entresto Leads Take-Off Of Heart Failure Market
Entresto Facing Pressure From Diabetes Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel